retatrutide ly3437943 triple agonist glp-1 gip glucagon just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon receptor posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight LY3437943, a novel triple GIP,

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality

The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes

A recent study, published in the Journal of Pharmacy and Pharmacology Research, sugges

Medical-grade dual receptor agonist with expert physician monitoring and personalized weight loss protocols.

Under these circumstances: 503A pharmacies (state-regulated) may compound drugs for individual patients pursuant to specific United States Pharmacopeia (USP) standards

Heres how it works, whats included and how to join.